Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease

Experimental Neurology

Volumn 234, Issue 2, 2012, Pages 482-487

  Sonsalla, Patricia K ^a   Wong, Lai Yoong ^a   Harris, Suzan L ^a   Richardson, Jason R ^a   Khobahy, Ida ^b   Li, Wenhao ^b   Gadad, Bharathi S ^b   German, Dwight C ^b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Animal model; Caffeine; Dopamine neurons; Microglia; Miniosmotic pump; MPP +; PD; Progressive neurodegeneration

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ADENOSINE RECEPTOR; CAFFEINE; DOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CHRONIC DISEASE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; MALE; MICROGLIA; NERVE CELL NECROSIS; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; THERAPY DELAY;

ANIMALS; CAFFEINE; CELL COUNT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINERGIC NEURONS; MALE; NERVE DEGENERATION; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

EID: 84862821537     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.01.022     Document Type: Article

References (38)

1. Aguiar L.M., Nobre H.V., Macedo D.S., Oliveira A.A., Freitas R.M., Vasconcelos S.M., Cunha G.M., Sousa F.C., Viana G.S. Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacol. Biochem. Behav. 2006, 84:415-419.
2. Alfinito P.D., Wang S.P., Manzino L., Rijhsinghani S., Zeevalk G.D., Sonsalla P.K. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J. Neurosci. 2003, 23:10982-10987.
3. Appel S.H., Beers D.R., Henkel J.S. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?. Trends Immunol. 2009, 31:7-17.
4. Bienvenu T., Pons G., Rey E., Richard M.O., d'Athis P., Olive G. Effect of hypophysectomy on caffeine elimination in rats. Fundam. Clin. Pharmacol. 1990, 4:393-399.
5. Brothers H.M., Marchalant Y., Wenk G.L. Caffeine attenuates lipopolysaccharide-induced neuroinflammation. Neurosci. Lett. 2010, 480:97-100.
6. Carta A.R., Kachroo A., Schintu N., Xu K., Schwarzschild M.A., Wardas J., Morelli M. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurochem. 2009, 111:1478-1489.
7. Chen J.F., Xu K., Petzer J.P., Staal R., Xu Y.H., Beilstein M., Sonsalla P.K., Castagnoli K., Castagnoli N., Schwarzschild M.A. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 2001, 21:RC143.
8. Costenla A.R., Cunha R.A., de Mendonca A. Caffeine, adenosine receptors, and synaptic plasticity. J. Alzheimers Dis. 2010, 20(Suppl. 1):S25-S34.
9. Dehmer T., Lindenau J., Haid S., Dichgans J., Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 2000, 74:2213-2216.
10. Fiebich B.L., Biber K., Lieb K., van Calker D., Berger M., Bauer J., Gebicke-Haerter P.J. Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 1996, 18:152-160.
11. Gandhi K.K., Williams J.M., Menza M., Galazyn M., Benowitz N.L. Higher serum caffeine in smokers with schizophrenia compared to smoking controls. Drug Alcohol Depend. 2010, 110:151-155.
12. Geraets L., Moonen H.J.J., Wouters E.F.M., Bast A., Hageman G.J. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations. Biochem. Pharmacol. 2006, 72:902-910.
13. German D.C., Manaye K.F. Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat. J. Comp. Neurol. 1993, 331:297-309.
14. Guerreiro S., Toulorge D., Hirsch E., Marien M., Sokoloff P., Michel P.P. Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. Mol. Pharmacol. 2008, 74:980-989.
15. Hasko G., Linden J., Cronstein B., Pacher P., Hasko G., Linden J., Cronstein B., Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discovery 2008, 7:759-770.
16. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
17. Hornykiewicz O. The neurobiology of dopamine. Brain Dopamine in Parkinson's Disease and Other Neurological Disturbances 1979, 633-654. Academic Press. A.S. Horn, J. Korf, B.H.C. Westerink (Eds.).
18. Joghataie M.T., Roghani M., Negahdar F., Hashemi L. Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence. Parkinsonism Relat. Disord. 2004, 10:465-468.
19. Kachroo A., Irizarry M.C., Schwarzschild M.A. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp. Neurol. 2010, 223:657-661.
20. Kalda A., Yu L., Oztas E., Chen J.-F. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease. J. Neurol. Sci. 2006, 248:9-15.
21. +, specifically impairs mitochondrial transport in dopamine axons. J. Neurosci. 2011, 31(19):7212-7221.
22. Morelli M., Carta A.R., Kachroo A., Schwarzschild M.A. Pathophysiological roles for purines: adenosine, caffeine and urate. Prog. Brain Res. 2011, 183:183-208.
23. Nomura D.K., Morrison B.E., Blankman J.L., Long J.Z., Kinsey S.G., Marcondes M.C.G., Ward A.M., Hahn Y.K., Lichtman A.H., Conti B., Cravatt B.F. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011, 334:809-813.
24. Orr A.G., Orr A.L., Li X.-J., Gross R.E., Traynelis S.F. Adenosine A(2A) receptor mediates microglial process retraction. Nat. Neurosci. 2009, 12:872-878.
25. Paxinos G., Watson C. The rat brain in stereotaxic coordinates-Second Edition 1986, Academinc Press, Inc., Orlando, FL.
26. Pickrell A.M., Pinto M., Hida A., Moraes C.T. Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurosci. 2011, 31:17649-17658.
27. Pierri M., Vaudano E., Sager T., Englund U. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 2005, 48:517-524.
28. Rebola N., Simões A.P., Canas P.M., Tomé A.R., Andrade G.M., Barry C.E., Agostinho P.M., Lynch M.A., Cunha R.A. Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. J. Neurochem. 2011, 117:100-111.
29. Saura J., Angulo E., Ejarque A., Casado V., Tusell J.M., Moratalla R., Chen J.F., Schwarzschild M.A., Lluis C., Franco R., Serratosa J. Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J. Neurochem. 2005, 95:919-929.
30. Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., Carta A.R., Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., Carta A.R. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur. J. Neurosci. 2009, 29:954-963.
31. Stavric B., Klassen R., Watkinson B., Karpinski K., Stapley R., Fried P. Variability in caffeine consumption from coffee and tea: possible significance for epidemiological studies. Food Chem. Toxicol. 1988, 26:111-118.
32. Trincavelli M.L., Melani A., Guidi S., Cuboni S., Cipriani S., Pedata F., Martini C. Regulation of A(2A) adenosine receptor expression and functioning following permanent focal ischemia in rat brain. J. Neurochem. 2008, 104:479-490.
33. Vyas I., Heikkila R.E., Nicklas W.J. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J. Neurochem. 1986, 46:1501-1507.
34. Xu K., Xu Y.H., Chen J.F., Schwarzschild M.A. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience 2010, 167:475-481.
35. +). Exp. Neurol. 2006, 200:172-183.
36. Yu L., Shen H.-Y., Coelho J.E., Araujo I.M., Huang Q.-Y., Day Y.-J., Rebola N., Canas P.M., Rapp E.K., Ferrara J., Taylor D., Muller C.E., Linden J., Cunha R.A., Chen J.-F. Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann. Neurol. 2008, 63:338-346.
37. Zeevalk G.D., Manzino L., Sonsalla P.K. NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum. Exp. Neurol. 2000, 161:638-646.
38. Zeevalk G.D., Manzino L., Sonsalla P.K., Bernard L.P. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp. Neurol. 2007, 203:512-520.